Christopher Raymond
Stock Analyst at Piper Sandler
(3.55)
# 888
Out of 4,681 analysts
122
Total ratings
54.46%
Success rate
4.11%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics | Upgrades: Overweight | $3 → $13 | $3.96 | +228.28% | 2 | Nov 18, 2024 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $4 → $5 | $0.83 | +505.47% | 4 | Nov 6, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,242 → $1,195 | $762.34 | +56.75% | 6 | Nov 1, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $66 → $76 | $44.74 | +69.87% | 7 | Sep 23, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $107 → $122 | $65.04 | +87.58% | 14 | Sep 5, 2024 | |
| IOBT IO Biotech | Maintains: Overweight | $10 | $0.90 | +1,012.47% | 2 | Sep 3, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $196 → $209 | $181.77 | +14.98% | 10 | Aug 23, 2024 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $33 | $15.86 | +108.07% | 1 | Aug 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $500 → $535 | $465.73 | +14.87% | 7 | Aug 2, 2024 | |
| BIIB Biogen | Maintains: Overweight | $335 → $313 | $164.23 | +90.59% | 18 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $7 | $3.08 | +127.27% | 2 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $5.54 | +170.76% | 6 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $78 → $104 | $97.62 | +6.54% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $8.48 | +395.28% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $26.63 | +69.01% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $21 | $1.66 | +1,165.06% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $27 → $1.5 | $0.53 | +182.33% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $130 | $47.60 | +173.11% | 4 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $9.47 | +132.31% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $2.13 | +87.79% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $6.64 | +276.51% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $278.10 | +3.56% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $58.87 | -30.36% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $58.53 | -52.16% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $94.27 | -57.57% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.79 | +1,454.40% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $4.35 | +2,106.90% | 2 | Mar 13, 2020 |
Aclaris Therapeutics
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.96
Upside: +228.28%
Karyopharm Therapeutics
Nov 6, 2024
Maintains: Overweight
Price Target: $4 → $5
Current: $0.83
Upside: +505.47%
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,242 → $1,195
Current: $762.34
Upside: +56.75%
Biohaven
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $44.74
Upside: +69.87%
BioMarin Pharmaceutical
Sep 5, 2024
Maintains: Overweight
Price Target: $107 → $122
Current: $65.04
Upside: +87.58%
IO Biotech
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.90
Upside: +1,012.47%
AbbVie
Aug 23, 2024
Maintains: Overweight
Price Target: $196 → $209
Current: $181.77
Upside: +14.98%
Tyra Biosciences
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $15.86
Upside: +108.07%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Overweight
Price Target: $500 → $535
Current: $465.73
Upside: +14.87%
Biogen
Jul 12, 2024
Maintains: Overweight
Price Target: $335 → $313
Current: $164.23
Upside: +90.59%
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $3.08
Upside: +127.27%
May 24, 2024
Maintains: Overweight
Price Target: $15
Current: $5.54
Upside: +170.76%
May 3, 2024
Maintains: Neutral
Price Target: $78 → $104
Current: $97.62
Upside: +6.54%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $8.48
Upside: +395.28%
Apr 2, 2024
Initiates: Overweight
Price Target: $45
Current: $26.63
Upside: +69.01%
Mar 8, 2024
Maintains: Overweight
Price Target: $11 → $21
Current: $1.66
Upside: +1,165.06%
Dec 22, 2023
Downgrades: Neutral
Price Target: $27 → $1.5
Current: $0.53
Upside: +182.33%
Oct 25, 2023
Maintains: Overweight
Price Target: $135 → $130
Current: $47.60
Upside: +173.11%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $9.47
Upside: +132.31%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $2.13
Upside: +87.79%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $6.64
Upside: +276.51%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $278.10
Upside: +3.56%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $58.87
Upside: -30.36%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $58.53
Upside: -52.16%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $94.27
Upside: -57.57%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.79
Upside: +1,454.40%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $4.35
Upside: +2,106.90%